$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000112623415000102 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$39.20M	$334.0K
YoY Change	11635.03%	10.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.400M	$3.300M
YoY Change	154.55%	65.0%
% of Gross Profit
Research & Development	$17.98M	$6.387M
YoY Change	181.52%	0.69%
% of Gross Profit
Depreciation & Amortization	$300.0K	$300.0K
YoY Change	0.0%	50.0%
% of Gross Profit
Operating Expenses	$26.35M	$9.638M
YoY Change	173.37%	15.51%
Operating Profit	$12.85M	-$9.304M
YoY Change	-238.09%	15.69%
Interest Expense	$0.00	$0.00
YoY Change
% of Operating Profit	0.0%
Other Income/Expense, Net	$11.00K	$68.00K
YoY Change	-83.82%	-37.04%
Pretax Income	$12.86M	-$9.236M
YoY Change	-239.23%	16.41%
Income Tax	$1.669M	$0.00
% Of Pretax Income	12.98%
Net Earnings	$11.19M	-$9.236M
YoY Change	-221.16%	16.41%
Net Earnings / Revenue	28.55%	-2765.27%
Basic Earnings Per Share	$0.40	-$0.33
Diluted Earnings Per Share	$0.35	-$0.33
COMMON SHARES
Basic Shares Outstanding	28.22M shares	27.61M shares
Diluted Shares Outstanding	31.92M shares	27.61M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$214.4M	$84.00M
YoY Change	155.24%	31.25%
Cash & Equivalents	$206.6M	$83.71M
Short-Term Investments	$7.800M	$200.0K
Other Short-Term Assets	$11.20M	$700.0K
YoY Change	1500.0%	0.0%
Inventory
Prepaid Expenses	$11.22M	$679.0K
Receivables
Other Receivables
Total Short-Term Assets	$251.1M	$85.31M
YoY Change	194.34%	29.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.028M	$6.434M
YoY Change	24.77%	9.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.028M	$6.434M
YoY Change	24.77%	9.25%
TOTAL ASSETS
Total Short-Term Assets	$251.1M	$85.31M
Total Long-Term Assets	$8.028M	$6.434M
Total Assets	$259.1M	$91.74M
YoY Change	182.45%	28.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.113M	$972.0K
YoY Change	323.15%	12.37%
Accrued Expenses	$9.295M	$2.381M
YoY Change	290.38%	18.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$555.0K	$190.0K
YoY Change	192.11%	7.34%
Total Short-Term Liabilities	$17.56M	$3.632M
YoY Change	383.54%	15.63%
LONG-TERM LIABILITIES
Long-Term Debt	$494.0K	$986.0K
YoY Change	-49.9%	-13.2%
Other Long-Term Liabilities	$8.200M	$7.300M
YoY Change	12.33%	-1.35%
Total Long-Term Liabilities	$8.734M	$8.286M
YoY Change	5.41%	-2.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.56M	$3.632M
Total Long-Term Liabilities	$8.734M	$8.286M
Total Liabilities	$26.30M	$11.92M
YoY Change	120.64%	2.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.93M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$491.0K	$182.0K
YoY Change	169.78%
Treasury Stock Shares
Shareholders Equity	$232.8M	$79.80M
YoY Change
Total Liabilities & Shareholders Equity	$259.1M	$91.74M
YoY Change	182.45%	28.03%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	$11.19M	-$9.236M
YoY Change	-221.16%	16.41%
Depreciation, Depletion And Amortization	$300.0K	$300.0K
YoY Change	0.0%	50.0%
Cash From Operating Activities	-$2.300M	-$6.100M
YoY Change	-62.3%	-7.58%
INVESTING ACTIVITIES
Capital Expenditures	$733.0K	$93.00K
YoY Change	688.17%	50.0%
Acquisitions		$0.00
YoY Change
Other Investing Activities	$4.600M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$3.885M	-$93.00K
YoY Change	-4277.42%	-113.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$14.67M	-$28.63M
YoY Change	-48.75%	-41.62%
Debt Paid & Issued, Net	$39.00K	$38.00K
YoY Change	2.63%	2.7%
Cash From Financing Activities	$14.63M	$28.58M
YoY Change	-48.83%	-41.63%
NET CHANGE
Cash From Operating Activities	-2.300M	-6.100M
Cash From Investing Activities	$3.885M	-$93.00K
Cash From Financing Activities	$14.63M	$28.58M
Net Change In Cash	$18.51M	$28.49M
YoY Change	-35.03%	-42.62%
FREE CASH FLOW
Cash From Operating Activities	-$2.300M	-$6.100M
Capital Expenditures	$733.0K	$93.00K
Free Cash Flow	-$3.033M	-$6.193M
YoY Change	-51.03%	-7.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3251000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8366000	USD
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28596319	shares
CY2015Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2015Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	190404000	USD
CY2015Q1	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	206593000	USD
CY2014Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1023000	USD
CY2015Q1	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1031000	USD
CY2014Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	88000	USD
CY2015Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	257000	USD
CY2014Q4	nlnk	Lab Equipment LabEquipment	4110000	USD
CY2015Q1	nlnk	Lab Equipment LabEquipment	4641000	USD
CY2014Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2015Q1	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2014Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	13000	USD
CY2015Q1	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	270000	USD
CY2014Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	12554000	USD
CY2015Q1	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	13287000	USD
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3716000	USD
CY2015Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	11046000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2412000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4113000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9367000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9295000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4955000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5259000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	236838000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	254966000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2100000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3200000	USD
CY2014Q4	us-gaap	Assets Assets	238062000	USD
CY2015Q1	us-gaap	Assets Assets	259127000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	230463000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	251099000	USD
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2015Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	36000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61291000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83713000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206593000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22422000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16189000	USD
CY2014Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	12393000	USD
CY2015Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	7776000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27991242	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28533836	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27980849	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28517195	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	280000	USD
CY2015Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	285000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	85000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1238000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1216000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12966000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3478000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1085000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1024000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7100000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7400000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	256000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	304000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2015Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-4618000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1669000	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9236000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	12859000	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	255000	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	15604000	USD
CY2015Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	14190000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-129000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1629000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-125000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1414000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	21000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	21000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9549000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1077000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7330000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-94000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2892000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	6000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	4000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	6000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	23000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	17000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6022000	USD
CY2015Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6059000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	34285000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	26296000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238062000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259127000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25021000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17562000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9264000	USD
CY2015Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8734000	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	29546000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	157000	USD
CY2015Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	555000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	941000	USD
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	494000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28582000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14625000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6067000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-93000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3885000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2321000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9236000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	11190000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	9638000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	26347000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9304000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12848000	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	50000	USD
CY2015Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	68000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	182000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	269000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	733000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8333000	USD
CY2015Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11224000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28811000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14942000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-9236000	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	11190000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1399000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1556000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7599000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8028000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	38000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	39000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6387000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17981000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33119000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21929000	USD
CY2014Q1	us-gaap	Revenue From Grants RevenueFromGrants	334000	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	9649000	USD
CY2014Q1	us-gaap	Revenues Revenues	334000	USD
CY2015Q1	us-gaap	Revenues Revenues	39195000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2105000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3191000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	329402	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	213192	shares
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13534000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3191000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1408000	USD
CY2015Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	6248	shares
CY2015Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	269000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	203777000	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	232831000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	222000	USD
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	491000	USD
CY2014Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1800000	USD
CY2015Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	310000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27605910	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31919318	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27605910	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28218631	shares
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for cancer and other diseases. NewLink initiated operations in April of 2000.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2005, NewLink created a partially owned subsidiary, BioProtection Systems Corporation (BPS). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. On January 7, 2011, NewLink acquired all of the minority interest in BPS, by merging a newly-formed subsidiary of NewLink with BPS, with BPS as the surviving corporation resulting in NewLink owning all the outstanding capital stock of BPS. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, NewLink created a wholly-owned subsidiary, NewLink International (NI). NewLink plans to conduct all or a portion of its operations outside of the United States through NI. In 2014, NewLink created another wholly-owned subsidiary, NewLink Global (NG), which was subsequently merged into NewLink during 2014.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company earned net income of </font><font style="font-family:inherit;font-size:10pt;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ending</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, primarily as a result of earning a milestone payment pursuant to a license and collaboration agreement the Company entered into with Merck, Sharpe and Dohme Corp., or Merck, in 2014. The Company has managed its liquidity needs historically through a series of capital market transactions. On February 4, 2013, the Company completed an offering of its common stock. The Company sold </font><font style="font-family:inherit;font-size:10pt;">4,600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$11.40</font><font style="font-family:inherit;font-size:10pt;"> per share raising a total of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink entered into a sales agreement with Cantor Fitzgerald & Co., dated as of September 5, 2013, under which NewLink may sell up to </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of its common stock in one or more placements at prevailing market prices for its common stock (the ATM Offering). Any such sales would be effected pursuant to its registration statement on Form S-3 (333-185721), declared effective by the SEC on January 4, 2013. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had sold </font><font style="font-family:inherit;font-size:10pt;">1,833,838</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the ATM Offering, raising a total of </font><font style="font-family:inherit;font-size:10pt;">$45.2 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds. On </font><font style="font-family:inherit;font-size:10pt;">March 3, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had completed the sale of </font><font style="font-family:inherit;font-size:10pt;">2,163,240</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the ATM Offering, raising a total of </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds. </font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying financial statements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three months then ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the ATM Offering prior to </font><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in 2014, as well as an additional milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements well into 2016, although not through commercialization and launch of revenue producing products. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-15-000102-index-headers.html	Edgar Link	pending
0001126234-15-000102-index.html	Edgar Link	pending
0001126234-15-000102.txt	Edgar Link	pending
0001126234-15-000102-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
newlinklogorgbwtaga01a01.jpg	Edgar Link	pending
nlnk-20150331.xml	Edgar Link	completed
nlnk-20150331.xsd	Edgar Link	pending
nlnk-20150331x10q.htm	Edgar Link	pending
nlnk-20150331xex101.htm	Edgar Link	pending
nlnk-20150331xex311.htm	Edgar Link	pending
nlnk-20150331xex312.htm	Edgar Link	pending
nlnk-20150331xex321.htm	Edgar Link	pending
nlnk-20150331_cal.xml	Edgar Link	unprocessable
nlnk-20150331_def.xml	Edgar Link	unprocessable
nlnk-20150331_lab.xml	Edgar Link	unprocessable
nlnk-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2015 Q1 Form 10-Q Financial Statement

#000112623415000102 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2015 Q1 Form 10-Q Financial Statement

#000112623415000102 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo